Albert S G, DeLeon M J, Silverberg A B
Department of Internal Medicine, the Division of Endocrinology, St. Louis University Health Sciences Center, St. Louis, MO 63110, USA.
Crit Care Med. 2001 Mar;29(3):668-70. doi: 10.1097/00003246-200103000-00039.
Whereas the antifungal azole ketoconazole interferes with steroidogenesis and can cause adrenal insufficiency, fluconazole in standard doses is thought to not interfere with cortisol production. The objective was to evaluate the effect of high-dose fluconazole therapy on adrenal function in critically ill patients in an intensive care setting.
Descriptive case reports.
Medical intensive care unit in a university hospital.
Two patients, a 77-yr-old man (case 1) with esophageal cancer and a 66-yr-old woman (case 2) with multiple organ failure developed reversible adrenal insufficiency temporally related to the institution and withdrawal of high-dose fluconazole.
Short cosyntropin (adrenocorticotropic hormone; ACTH) stimulation tests.
Two days after high-dose fluconazole in case 1, the serum ACTH level was 121 pg/mL (normal range is 9-52 pg/mL), and the peak cortisol after ACTH stimulation was 15.5 microg/dL (normal response is >or=18 microg/dL). Eleven days after discontinuation of fluconazole, the peak cortisol level after ACTH stimulation was 43.4 microg/dL. Twenty-four hours after high-dose fluconazole in case 2, an ACTH stimulation test had a low peak serum cortisol of 16.8 microg/dL. Fluconazole was withdrawn, and 5 days later, the peak stimulated cortisol was 20.6 microg/dL.
Although fluconazole is the therapy of choice for patients in the intensive care setting with Candida infections, two patients with multiple organ failure who received high-dose fluconazole appeared to develop adrenal insufficiency. Although preliminary and anecdotal, these data suggest a need to further investigate the possibility that high-dose fluconazole might cause adrenal insufficiency in already compromised critically ill patients.
抗真菌唑类药物酮康唑会干扰类固醇生成并可导致肾上腺功能不全,而标准剂量的氟康唑被认为不会干扰皮质醇的产生。本研究目的是评估在重症监护环境下大剂量氟康唑治疗对重症患者肾上腺功能的影响。
描述性病例报告。
大学医院的内科重症监护病房。
两名患者,一名77岁患有食管癌的男性(病例1)和一名66岁患有多器官功能衰竭的女性(病例2),均出现了与大剂量氟康唑的使用及停用时间相关的可逆性肾上腺功能不全。
短程促肾上腺皮质激素(ACTH)刺激试验。
病例1在使用大剂量氟康唑两天后,血清促肾上腺皮质激素水平为121 pg/mL(正常范围为9 - 52 pg/mL),ACTH刺激后的皮质醇峰值为15.5 μg/dL(正常反应为≥18 μg/dL)。停用氟康唑11天后,ACTH刺激后的皮质醇峰值水平为43.4 μg/dL。病例2在使用大剂量氟康唑24小时后,ACTH刺激试验的血清皮质醇峰值较低,为16.8 μg/dL。停用氟康唑,5天后,刺激后的皮质醇峰值为20.6 μg/dL。
尽管氟康唑是重症监护病房念珠菌感染患者的首选治疗药物,但两名接受大剂量氟康唑治疗的多器官功能衰竭患者似乎出现了肾上腺功能不全。尽管这些数据是初步的且为个案,但表明有必要进一步研究大剂量氟康唑可能导致本已病情严重的重症患者出现肾上腺功能不全的可能性。